Reflections of a Fireside Chat from the World Orphan Drug Congress 2020
September 9, 2020 |
Hear from Trish Shepherd COO, Patient & Brand Communications, OPEN Health
From junior doctor to gene therapy CEO, how one person’s drive to make rare disease curable is shaping the future of medicine.
It was a truly touching story to hear Dr Gaspar recant his early days working with young, severely immunocompromised patients at Great Ormond Street. Dr Gaspar knew that most of his patients would die within their first year without any therapy. Although bone marrow transplantation was an option for some patients, it was not without risk of complications.
THE POWER OF ONE
Dr Gaspar was first told of a single patient candidate for gene therapy while doing his rounds in 1993. He was initially convinced it was a Senior Doctor prank on a trainee, but as the years passed Dr. Gaspar saw that one patient return to the hospital with a fully healthy immune system and he was inspired to return to the lab to explore. And he did. In 2001, he went on to test the innovations he and his colleague were exploring in human clinical trials. The success these approaches received garnered much interest: first beyond the academic setting and then across regions and continents. The next step was clear – a commercial entity was needed to deliver more solutions to more people.
The result was Orchard Therapeutics, a company dedicated to setting up a process that enables the treatment cells to travel so that patients, who are already living with debilitating diseases, do not have to. As a business, Orchard Therapeutics want to introduce as many therapies as possible and, in order to enable a broader reach, are eager to work with regulators to explore reimbursement models from single payments, to annualised payments or payment by results.
AN UNBEATABLE MOMENT
When asked what it is like as a clinician to see this level of success, Dr Gaspar replies that there is nothing more rewarding than treating a patient with a therapy that you have created – it is, truly, an unbeatable moment.
Dr Gaspar has now moved on from his clinical duties to focus fully on his CEO responsibilities at Orchard Therapeutics, but remains certain that the options for clinicians when faced with rare genetic disease diagnoses, such as Severe Combined Immune Deficiency (SKID) and Metachromatic leukodystrophy (MLD), are different. The conversations with the families of patients will be entirely more positive in light of the new available options. The face of the disease is, thanks to Dr Gaspar and his colleagues’ work, now permanently changing for the better.
From this fireside chat, you can see the desire to introduce more curative therapies still burns bright.
DISCOVERING THE MOMENTS THAT MATTER MOST TO PATIENTS AND FAMILIES
Here at OPEN Health Patient & Brand Communications we pride ourselves on our deep understanding of the patient experience in rare disease and have significant expertise in consulting on the delivery of innovative treatments in complex treatment pathways, as well as providing niche patient support platforms to help patients and their families better understand novel treatments.
If you’d like to learn more, we’d love to hear from you and look forward to working together to help introduce more novel therapies to the people that need them most.
Trish Shepherd
COO, Patient & Brand Communications
This content was provided by OPEN Health
Company Details
Latest Content from OPEN Health
Digital Therapeutics Landscape in Europe
OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK
OPEN Health’s virtual reflections on the World Orphan Drug Congress US
Another congress attended in this virtual world with learnings gathered and connections made across the rare disease community. It was great to be joined by many colleagues from all our...
A day in the life of the Global Head of Publications
We asked Mina Patel to give us an insight into her role as Global Head of Publications at OPEN Health
Striving to become more patient-centric?
Explore more with OPEN Health
Meet OPEN Health and Pharmerit Experts at the World Orphan Drug Virtual USA Congress
Join OPEN Health and Pharmerit – an OPEN Health Company at the World Orphan Drug Virtual Congress from August 24-27, 2020, as we present:Advanced Therapies Commercial: Tuesday, August 25Succeeding with Star Wars...
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !
OPEN Health Medical Communications is awarded Medical Affairs Agency of The Year at the Communiqué Awards 2020
We are delighted to announce that OPEN Health Medical Communications was named Medical Affairs Agency of the Year at the virtual 2020 Communiqué Awards ceremony on 02 July 2020.
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me.
Candice Subero to Lead Global Marketing for OPEN Health
OPEN Health is pleased to announce that Candice Subero has been named Global Marketing Lead, effective June 4, 2020. Candice will oversee strategic communications and marketing efforts across all OPEN...
The RARE Youth Revolution has begun
OPEN Health are proud to support RARE Revolution Magazine who have launched a dedicated RARE youth online platform powering up the voices of the youth rare disease community.